Updated:
Cosmos Health Inc.
Cosmos Health Inc. first appeared in public disclosures as a pharmaceutical and nutraceutical company, building its operations around generic drug...
Cosmos Health Inc.
Cosmos Health Inc. first appeared in public disclosures as a pharmaceutical and nutraceutical company, building its operations around generic drug manufacturing and distribution. The firm, headquartered in the United States, maintains a presence in the European market through subsidiaries. Wealth-origin context is not publicly attributed to a specific family branch. The firm's strategy centers on vertical integration within healthcare: it owns manufacturing facilities, manages a portfolio of branded and generic drugs, and operates a distribution network. Cosmos Health has disclosed acquisitions of European pharmaceutical companies to expand its geographic footprint. It also develops over-the-counter and prescription products. The company's structure includes both operating subsidiaries and investment vehicles. Cosmos Health reported revenue of $50 million in its 2023 fiscal year (public record). The firm employs approximately 200 people across its global operations. No recent operational events were verifiable from public sources beyond routine SEC filings. The firm does not disclose AUM or assets under advisory. Cosmos Health differs from pure family offices by functioning as a publicly traded operating company. Its governance follows corporate board structure rather than family-office hierarchy. The firm's mandate is operational control of healthcare assets, not passive wealth management.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Does Cosmos Health operate as a single family office or a publicly held company?
Cosmos Health Inc. is a publicly traded entity (per SEC filings). It operates as a holding company for healthcare businesses rather than as a private family office. Its structure includes both manufacturing operations and pharmaceutical distribution.
What is the primary investment strategy at Cosmos Health?
The firm pursues vertical integration in healthcare, owning manufacturing facilities and distribution networks. It targets acquisitions of generic drug manufacturers and nutraceutical companies in North America and Europe (public record). The strategy combines organic growth with selective M&A.
Who controls investment decisions at Cosmos Health?
Cosmos Health is governed by a board of directors and executive officers, as disclosed in public filings. No single family or individual investment committee is publicly named. The firm's management team oversees both operational and capital allocation decisions.
What is the geographic focus of Cosmos Health?
The firm maintains operations in the United States and Europe. It owns manufacturing facilities in both regions and distributes products through its network. Recent public filings confirm EU-based subsidiaries (per SEC filings).
Does Cosmos Health disclose assets under management or portfolio size?
No. Cosmos Health does not publish AUM figures. Its most recent annual report (2023) disclosed $50 million in revenue, but balance-sheet assets are not broken out by investment portfolio (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: